Singapore, April 30 -- In a historic step for the Egyptian pharmaceutical industry that reinforces its global leadership, the Thai Food and Drug Administration (Thai FDA) has officially approved Ravidasvir as a safe and effective treatment against the hepatitis C virus (HCV).

This approval is part of a robust clinical and regulatory ecosystem spearheaded by the Thai FDA, organically linked with the Government Pharmaceutical Organization (GPO), scientific expertise centres, and clinical trial sites in prestigious Thai hospitals and institutions, including King Chulalongkorn Memorial Hospital, Bamrasnaradura Infectious Diseases Institute, Nakornping Hospital, and Maharaj Nakorn Chiang Mai Hospital.

The drug has demonstrated clinical effic...